CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by PFG Investments LLC

PFG Investments LLC lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 7.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,651 shares of the company’s stock after selling 755 shares during the period. PFG Investments LLC’s holdings in CRISPR Therapeutics were worth $453,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Capital International Investors grew its stake in shares of CRISPR Therapeutics by 27.8% during the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares during the period. Vanguard Group Inc. increased its holdings in CRISPR Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock valued at $111,564,000 after buying an additional 46,148 shares in the last quarter. SR One Capital Management LP acquired a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $71,496,000. Dimensional Fund Advisors LP boosted its stake in shares of CRISPR Therapeutics by 2.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock worth $51,326,000 after acquiring an additional 19,094 shares in the last quarter. Finally, Farallon Capital Management LLC purchased a new position in CRISPR Therapeutics in the 2nd quarter valued at approximately $28,625,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CRSP. Barclays cut their price target on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 6th. Truist Financial reduced their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Royal Bank of Canada dropped their price objective on shares of CRISPR Therapeutics from $60.00 to $53.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Chardan Capital reduced their target price on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, Stifel Nicolaus dropped their price target on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $75.19.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $48.94 on Wednesday. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of -17.99 and a beta of 1.68. CRISPR Therapeutics AG has a one year low of $38.16 and a one year high of $91.10. The company’s 50 day moving average price is $47.18 and its 200 day moving average price is $52.60.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The firm had revenue of $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. During the same period last year, the firm earned ($0.98) earnings per share. CRISPR Therapeutics’s revenue for the quarter was down 99.3% on a year-over-year basis. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.